



## **Xintela granted 1 million SEK from Vinnova**

**Lund, Sweden, May 8, 2020 - Xintela has been granted 1 million SEK from Vinnova in the call for "Innovations in the wake of the crisis - Restructuring of society, operations and production in the wake of the corona epidemic." The grant concerns the funding of a preclinical study to evaluate Xintela's stem cells for the treatment of Covid-19 patients with the fatal disease condition ARDS (Acute Respiratory Distress Syndrome).**

The project, which is partly financed by Vinnova, intends to evaluate safety and efficacy of Xintela's Mesenchymal Stem Cells (XSTEM®) in a preclinical model for ARDS, a disease condition that can affect Covid-19 patients. ARDS is a very serious and difficult-to-treat lung disease that requires oxygen therapy, often intensive care with a respirator, and leads to many deaths.

Xintela's stem cells will be tested in a validated ARDS model in collaboration with Associate Professor Sandra Lindstedt Ingemansson at the Department of Cardiothoracic Surgery and Transplantation at Skåne University Hospital in Lund. If the study is successful, the results will form the basis for an application to the Swedish Medical Products Agency to carry out clinical studies on Covid-19 patients with severe and deadly lung symptoms.

Xintela's application received a maximum grant in tough competition where 18 applications out of a total of 270 were approved. In total, SEK 10 million was available, with a maximum amount per application of SEK 1 million.

- To meet the huge need for a life-saving treatment for Covid-19 patients, we are expanding our development work on our selected and quality-assured stem cells. Stem cells have the potential to treat Covid-19 patients through the cells' anti-inflammatory and immunomodulatory effects by reducing the severe cytokine storm that affects the seriously ill patients. The fact that our project was approved in competition with a large number of applications is an exciting quality stamp for our efforts, says Xintela's CEO Evy Lundgren-Åkerlund.

*This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 8th of May 2020.*

### **Xintela AB (publ)**

Evy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: [evy@xintela.se](mailto:evy@xintela.se)

Medicon Village

223 81 Lund, Sweden

[www.xintela.se](http://www.xintela.se)

### **About Xintela**

Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma. Xintela is listed on Nasdaq First North Growth Market

Press release

Xintela AB (publ)  
556780-3480  
2020-05-08



Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se).